Aneurysms of the abdominal aorta have traditionally required an open approach, a high-risk and bloody surgery with a long recovery time. In recent years this practice has been supplanted in certain patient populations by endovascular aortic repair (EVAR). In this approach, a graft is introduced into the aorta through the femoral artery, requiring a shorter hospital stay and less blood loss. One company actively involved in this field is Bolton Medical, based out of Florida and Barcelona. We last reported on their Treovance Abominal Stent-Graft in May 2011, when the ADVANCE trial of this device first started (link). Now, patient enrollment has been completed, and the results are reported to be encouraging, although the final data isn’t available yet.
“The Bolton ADVANCE study has been completed and so far the device shows promising results”, said Prof. Roberto Chiesa, Principal Investigator for the ADVANCE Study “I think that the Treovance Abdominal Stent-Graft continues a new generation of devices focused on providing: low-profile systems, precise
deployment, stent-graft repositioning and additionally offers features to minimize late disconnections”
The Treovance system is used with the Navitel delivery system, a low profile set-up with a sheath that detaches completely. The stent-graft is available in varying sizes and is flexible enough to use in patients with aortas that are difficult to navigate. Additionally, multiple fixation points, both supra- and infra-renal, are available for securing the stent-graft within the native aorta. In addition to the Treovance system for abdominal aortic pathology, the company manufactures a stent for thoracic aortic aneurysms called the Relay thoracic stent-graft, which is currently under investigative use in the United States.